Covaxin receives certificate of Good Manufacturing Practice from Hungarian authorities

HYDERABAD: In a move that could open the doors of the European market for indigenously developed Covid-19 vaccine Covaxin, Bharat Biotech has received a certificate of Good Manufacturing Practice (GMP) compliance for the vaccine from the Hungarian authorities.
The approval received is from the National Institute of Pharmacy and Nutrition Hungary certifying the GMP for the manufacture of Covaxin, Bharat Biotech said on Thursday.
“The certificate of GMP is now listed on the EudraGMDP database, which is the database of the European Community of manufacturing authorizations and certificates of the good manufacturing practice,” the company said.
With this, the company said it intends to submit documentation for Emergency Use Authorization (EUA) in several additional countries worldwide. Covaxin has already received EUA from around 16 countries, as per the company.
“With this approval, Bharat Biotech has achieved another significant milestone in innovating and manufacturing vaccines at global quality standards and moving forward in the ongoing fight against the Covid-19 pandemic. The recognition complements our commitment of driving world-class innovation and being a frontrunner in the research and development of vaccines,” it said.